We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » ABBOTT AND ASTRAZENECA ANNOUNCE COLLABORATION TO DEVELOP AND COMMERCIALIZE CRESTOR AND NEXT-GENERATION TRICOR FIXED-DOSE COMBINATION
ABBOTT AND ASTRAZENECA ANNOUNCE COLLABORATION TO DEVELOP AND COMMERCIALIZE CRESTOR AND NEXT-GENERATION TRICOR FIXED-DOSE COMBINATION
July 5, 2006
Abbott and AstraZeneca announced today a collaboration to co-develop and market a combination treatment that will target all three important blood lipids — LDL-C "bad" cholesterol, HDL-C "good" cholesterol, and triglycerides — in one single pill as part of a comprehensive treatment regimen. Under the agreement, the companies will initiate two parallel programs: a CRESTOR (rosuvastatin calcium)/TriCor (fenofibrate tablets) fixed-dose combination and a CRESTOR/ABT-335 combination. ABT-335 is Abbott's proprietary next-generation fenofibrate currently in Phase III clinical trials. PR Newswire
